Global (United States, European Union and China) Primary Biliary Cirrhosis Drug Market Research Report 2019-2025

1 Study Coverage

• 1.1 Primary Biliary Cirrhosis Drug Product Introduction
• 1.2 Market Segments
• 1.3 Key Primary Biliary Cirrhosis Drug Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type
  • 1.4.2 Budesonide
  • 1.4.3 FFP-104
  • 1.4.4 GSK-2330672
  • 1.4.5 MBX-8025
  • 1.4.6 NGM-282
  • 1.4.7 Others
• 1.5 Market by Application
  • 1.5.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application
  • 1.5.2 Clinic
  • 1.5.3 Hospital
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Primary Biliary Cirrhosis Drug Market Size, Estimates and Forecasts
  • 2.1.1 Global Primary Biliary Cirrhosis Drug Revenue 2015-2026
  • 2.1.2 Global Primary Biliary Cirrhosis Drug Sales 2015-2026
• 2.2 Global Primary Biliary Cirrhosis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Primary Biliary Cirrhosis Drug Competitor Landscape by Players

• 3.1 Primary Biliary Cirrhosis Drug Sales by Manufacturers
  • 3.1.1 Primary Biliary Cirrhosis Drug Sales by Manufacturers (2015-2020)
  • 3.1.2 Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2015-2020)
• 3.2 Primary Biliary Cirrhosis Drug Revenue by Manufacturers
  • 3.2.1 Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2015-2020)
  • 3.2.2 Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Primary Biliary Cirrhosis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Primary Biliary Cirrhosis Drug Revenue in 2019
  • 3.2.5 Global Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Primary Biliary Cirrhosis Drug Price by Manufacturers
• 3.4 Primary Biliary Cirrhosis Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Primary Biliary Cirrhosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Primary Biliary Cirrhosis Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
  • 4.1.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020)
  • 4.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020)
  • 4.1.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Primary Biliary Cirrhosis Drug Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Type (2021-2026)
  • 4.2.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Primary Biliary Cirrhosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
  • 5.1.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020)
  • 5.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2015-2020)
  • 5.1.3 Primary Biliary Cirrhosis Drug Price by Application (2015-2020)
• 5.2 Primary Biliary Cirrhosis Drug Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Primary Biliary Cirrhosis Drug Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Primary Biliary Cirrhosis Drug by Country
  • 6.1.1 North America Primary Biliary Cirrhosis Drug Sales by Country
  • 6.1.2 North America Primary Biliary Cirrhosis Drug Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
• 6.3 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

7 Europe

• 7.1 Europe Primary Biliary Cirrhosis Drug by Country
  • 7.1.1 Europe Primary Biliary Cirrhosis Drug Sales by Country
  • 7.1.2 Europe Primary Biliary Cirrhosis Drug Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
• 7.3 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Primary Biliary Cirrhosis Drug by Region
  • 8.1.1 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region
  • 8.1.2 Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
• 8.3 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Primary Biliary Cirrhosis Drug by Country
  • 9.1.1 Latin America Primary Biliary Cirrhosis Drug Sales by Country
  • 9.1.2 Latin America Primary Biliary Cirrhosis Drug Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
• 9.3 Central & South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Primary Biliary Cirrhosis Drug by Country
  • 10.1.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country
  • 10.1.2 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
• 10.3 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

11 Company Profiles

• 11.1 AlbireoPharma
  • 11.1.1 AlbireoPharma Corporation Information
  • 11.1.2 AlbireoPharma Description and Business Overview
  • 11.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
  • 11.1.5 AlbireoPharma Related Developments
• 11.2 CymaBay Therapeutics, Inc.
  • 11.2.1 CymaBay Therapeutics, Inc. Corporation Information
  • 11.2.2 CymaBay Therapeutics, Inc. Description and Business Overview
  • 11.2.3 CymaBay Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Products Offered
  • 11.2.5 CymaBay Therapeutics, Inc. Related Developments
• 11.3 Dr. Falk Pharma GmbH
  • 11.3.1 Dr. Falk Pharma GmbH Corporation Information
  • 11.3.2 Dr. Falk Pharma GmbH Description and Business Overview
  • 11.3.3 Dr. Falk Pharma GmbH Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Products Offered
  • 11.3.5 Dr. Falk Pharma GmbH Related Developments
• 11.4 Enanta Pharmaceuticals, Inc.
  • 11.4.1 Enanta Pharmaceuticals, Inc. Corporation Information
  • 11.4.2 Enanta Pharmaceuticals, Inc. Description and Business Overview
  • 11.4.3 Enanta Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
  • 11.4.5 Enanta Pharmaceuticals, Inc. Related Developments
• 11.5 GlaxoSmithKline Plc
  • 11.5.1 GlaxoSmithKline Plc Corporation Information
  • 11.5.2 GlaxoSmithKline Plc Description and Business Overview
  • 11.5.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Products Offered
  • 11.5.5 GlaxoSmithKline Plc Related Developments
• 11.6 Intercept Pharmaceuticals, Inc.
  • 11.6.1 Intercept Pharmaceuticals, Inc. Corporation Information
  • 11.6.2 Intercept Pharmaceuticals, Inc. Description and Business Overview
  • 11.6.3 Intercept Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
  • 11.6.5 Intercept Pharmaceuticals, Inc. Related Developments
• 11.7 Johnson & Johnson
  • 11.7.1 Johnson & Johnson Corporation Information
  • 11.7.2 Johnson & Johnson Description and Business Overview
  • 11.7.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Products Offered
  • 11.7.5 Johnson & Johnson Related Developments
• 11.8 MediGene AG
  • 11.8.1 MediGene AG Corporation Information
  • 11.8.2 MediGene AG Description and Business Overview
  • 11.8.3 MediGene AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 MediGene AG Primary Biliary Cirrhosis Drug Products Offered
  • 11.8.5 MediGene AG Related Developments
• 11.9 NGM Biopharmaceuticals, Inc.
  • 11.9.1 NGM Biopharmaceuticals, Inc. Corporation Information
  • 11.9.2 NGM Biopharmaceuticals, Inc. Description and Business Overview
  • 11.9.3 NGM Biopharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
  • 11.9.5 NGM Biopharmaceuticals, Inc. Related Developments
• 11.10 Virobay Inc.
  • 11.10.1 Virobay Inc. Corporation Information
  • 11.10.2 Virobay Inc. Description and Business Overview
  • 11.10.3 Virobay Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Products Offered
  • 11.10.5 Virobay Inc. Related Developments
• 11.1 AlbireoPharma
  • 11.1.1 AlbireoPharma Corporation Information
  • 11.1.2 AlbireoPharma Description and Business Overview
  • 11.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
  • 11.1.5 AlbireoPharma Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Primary Biliary Cirrhosis Drug Market Estimates and Projections by Region
  • 12.1.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Regions 2021-2026
• 12.2 North America Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
  • 12.2.1 North America: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
  • 12.2.2 North America: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
  • 12.2.3 North America: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
• 12.3 Europe Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
  • 12.3.2 Europe: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Primary Biliary Cirrhosis Drug Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Primary Biliary Cirrhosis Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Primary Biliary Cirrhosis Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details